Oregovomab

BIOLOGICAL17 trials

Sponsors

Canariabio Inc., AltaRex, Unither Pharmaceuticals, Gynecologic Oncology Group, Quest PharmaTech Inc.

Conditions

Adenocarcinoma of OvaryAdvanced epithelial ovarianCancer of OvaryCarcinoma, Ovarian EpithelialEpithelial Ovarian CancerFallopian Tube AdenocarcinomaFallopian Tube CancerFallopian Tube Carcinoma

Phase 1

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

TerminatedNCT00034138

Unither PharmaceuticalsOvarian Neoplasms

Start: 2002-03-31End: 2007-12-31Target: 24Updated: 2007-12-18

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

TerminatedNCT03100006

National Cancer Centre, SingaporeEpithelial Ovarian Cancer

Start: 2017-02-22End: 2020-04-17Updated: 2022-06-13

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

TerminatedNCT03162562

CanariaBio Inc.Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Recurrent +3

Start: 2017-05-30End: 2020-11-05Updated: 2020-12-22

Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

National Cancer Centre, SingaporeEpithelial Ovarian Cancer

Start: 2020-10-07End: 2022-07-31Target: 31Updated: 2021-12-01

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV

Start: 2021-03-17End: 2025-12-31Target: 54Updated: 2023-10-17

Phase 2

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

TerminatedNCT00034372

Unither PharmaceuticalsOvarian Neoplasms

Start: 2000-09-30End: 2007-12-31Target: 102Updated: 2007-12-18

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

TerminatedNCT00086632

Unither PharmaceuticalsOvarian Cancer

Start: 2004-07-31End: 2007-12-31Target: 40Updated: 2007-12-18

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

AltaRexFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Start: 1998-11-30Target: 102Updated: 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

AltaRexFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Start: 1998-04-30Target: 400Updated: 2013-11-06

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

CompletedNCT01616303

Quest PharmaTech Inc.Ovarian Neoplasms

Start: 2012-06-15End: 2018-10-12Updated: 2020-09-14

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

CompletedNCT01959672

University of NebraskaPancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage IA Pancreatic Cancer +6

Start: 2013-09-06End: 2018-12-01Updated: 2023-10-10

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruitingNCT05335993

CanariaBio Inc.Adenocarcinoma of Ovary, Peritoneal Cancer, Recurrent Carcinoma of Ovary +4

Start: 2022-07-25End: 2027-12-30Updated: 2026-04-03

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Active, not recruitingNCT05605535

CanariaBio Inc.Fallopian Tube Neoplasms, Ovarian Cancer, Ovarian Neoplasm Epithelial +2

Start: 2023-02-07End: 2027-09-15Target: 88Updated: 2026-04-01

Phase 3

Clinical Trial for Ovarian Cancer (OvaRex®)

TerminatedNCT00050375

Unither PharmaceuticalsOvarian Cancer

Start: 2002-12-31End: 2007-12-31Target: 354Updated: 2007-12-18

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruitingNCT04498117

CanariaBio Inc.Carcinoma, Ovarian Epithelial, Fallopian Tube Adenocarcinoma, Fallopian Tube Neoplasms +7

Start: 2020-08-25End: 2028-08-26Updated: 2026-04-01

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Active, not recruitingCTIS2024-519218-30-00

Canariabio Inc.Advanced epithelial ovarian, fallopian tube or peritoneal carcinoma

Start: 2021-05-26Target: 64Updated: 2025-12-01

Unknown Phase

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

WithdrawnNCT00551265

Gynecologic Oncology GroupFallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma +2

Start: 2007-10-31Updated: 2017-07-14

Related Papers

Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).

Journal of Clinical Oncology2025-05-28

Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.

Journal of Clinical Oncology2024-06-01

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Journal for ImmunoTherapy of Cancer2023-10-0118 citations

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.

Journal of Clinical Oncology2023-06-01

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.

Journal of Clinical Oncology2022-06-014 citations

Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.

2021-12-2824 citations

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.

Journal of Clinical Oncology2021-05-202 citations

Final survival follow-up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC in patients (pts) with recurrent platinum-resistant ovarian cancer (PROC).

Journal of Clinical Oncology2021-05-20

Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma

American Journal of Clinical Oncology2019-09-1021 citations

Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort

Annals of Oncology2018-10-012 citations

A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma.

Journal of Clinical Oncology2018-05-20

A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC).

Journal of Clinical Oncology2017-05-202 citations